In this captivating exploration, we delve into the cutting-edge world of cancer immunotherapy. Our 68-year-old patient battles advanced melanoma, a formidable adversary. But there’s hope—a novel treatment involving monoclonal antibodies that target a specific cell surface receptor on T lymphocytes
